NSCLC
These results highlight the unique features of TKI resistance in ALK-positive NSCLCs and provide the rationale for pursuing combinatorial therapeutics that are tailored to the precise resistance mechanisms identified in patients who relapse on crizotinib treatment.
These results highlight the unique features of TKI resistance in <span class="gene" id="22277784-8-65-68">ALK</span>-positive <span class="disease" id="22277784-8-78-83">NSCLC</span>s and provide the rationale for pursuing combinatorial therapeutics that are tailored to the precise resistance mechanisms identified in patients who relapse on crizotinib treatment.